Tests stem cells from umbilical cord or placenta for polycystic ovary syndrome
Tests donor stem cells given into a vein in adults with polycystic ovary syndrome.
Plain-language title generated from the registry record
Registry title: Safety of Cultured Allogeneic Adult Umbilical Cord or Placental Derived Mesenchymal Stem Cells for PCOS
Key facts
- Where
- Athens, GreeceSee the site
- Phase
- Phase 1
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for women aged 18 or older with polycystic ovary syndrome (PCOS) shown on an ultrasound. It tests stem cells given through a vein.
- Age
- 18 years or older
- Sex
- Women only
- Disease stage
- Polycystic ovary syndrome shown on an ultrasound
- Earlier treatment
- Not stated in the record. People with a previous organ transplant cannot join.
Main reasons for not taking part
- Active infection
- Active cancer
- Chronic failure of several organs
- Pregnancy
- Previous organ transplant
Read by machine on 12 November 2026.
Where in Greece
- Prodromos Stem Cell InstituteAthens, GreeceContact: Chadwick Prodromos, MDTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- The Foundation for Orthopaedics and Regenerative Medicine
- Trial code
- NCT06143527
- Record updated
- 20 October 2026
- Original description
This trial will study the safety and efficacy of cultured allogeneic adult umbilical cord or placental derived mesenchymal stem cells delivered intravenously for the treatment of Polycystic Ovary Syndrome.Read full original descriptionShow less
Safety of Cultured Allogeneic Adult Umbilical Cord or Placental Derived Mesenchymal Stem Cells for the Treatment of Polycystic Ovary Syndrome
This trial will study the safety and efficacy of cultured allogeneic adult umbilical cord or placental derived mesenchymal stem cells delivered intravenously for the treatment of Polycystic Ovary Syndrome.
Inclusion: Ultrasound documented poly cystic ovary syndrome.
Exclusion: Continued drug abuse; Previous organ transplant; Active infection; Active cancer; Chronic multisystem organ failure; Medical condition that would (based on the opinion of the investigator) compromise patient's safety; Hypersensitivity to sulfur; Clinically significant abnormalities on pre-treatment laboratory evaluation; Pregnancy; Inability to supply proper informed consent.